Want to see SXTP full AI Analyst Report?
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▲(200.00% Upside)
Action:Reiterated
Date:07/10/26
The score is held down primarily by ongoing large losses and significant, worsening cash burn relative to a very small revenue base. Technicals are mixed with only modest near-term stabilization and a weak longer-term trend, while valuation is hard to justify due to negative earnings. Offsetting factors include low reported debt/positive equity and positive corporate-development milestones around the tafenoquine babesiosis program, but these remain data- and timeline-dependent.
Positive Factors
Low Leverage / Stronger Balance Sheet
Minimal debt and positive equity (~$4.7M) reduce insolvency risk and give management flexibility to fund development or partner programs without immediate debt stress. A cleaner balance sheet supports strategic options and extends runway relative to heavily levered peers.
Negative Factors
High Cash Burn
Sustained and worsening negative operating and free cash flow (~-$8.2M TTM) rapidly depletes liquidity and forces recurring external financing. This structurally increases dilution risk, constrains R&D continuity, and raises the probability of funding-driven program delays absent material revenues or deals.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Stronger Balance Sheet
Minimal debt and positive equity (~$4.7M) reduce insolvency risk and give management flexibility to fund development or partner programs without immediate debt stress. A cleaner balance sheet supports strategic options and extends runway relative to heavily levered peers.
Read all positive factors
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.88M
Dividend YieldN/A
Average Volume (3M)199.18K
Price to Earnings (P/E)―
Beta (1Y)2.43
Revenue Growth66.12%
EPS Growth91.75%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.70Price Target Upside640.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an ap...
How the Company Makes Money
null...
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M |
| Gross Profit | 223.78K | 222.81K | -220.98K | -209.16K | 309.60K |
| EBITDA | -7.28M | -7.88M | -1.43M | -2.11M | -1.01M |
| Net Income | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
Balance Sheet | |||||
| Total Assets | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 3.39M | 2.14M | 264.87K | 115.40K |
| Total Debt | 152.78K | 155.89K | 172.67K | 22.42M | 18.80M |
| Total Liabilities | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Stockholders Equity | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
Cash Flow | |||||
| Free Cash Flow | -7.07M | -5.83M | -4.66M | -1.07M | -684.50K |
| Operating Cash Flow | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K |
| Investing Cash Flow | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K |
| Financing Cash Flow | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
0.50
Price Trends
1.53
Positive
1.80
Negative
3.01
Negative
Market Momentum
>-0.01
Positive
47.86
Neutral
15.50
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.53, and below the 200-day MA of 3.01, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 15.50 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $3.88M | -0.15 | -212.63% | ― | 66.12% | 91.75% | |
| ― | $2.55M | -0.09 | -168.95% | ― | ― | 84.00% | |
42 Neutral | $17.91M | -0.36 | -1335.64% | ― | ― | 66.47% | |
| ― | $3.13M | -0.09 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
SXTP
60 Degrees Pharmaceuticals, Inc.
1.55
-5.01
-76.37%
OGEN
Oragenics
0.56
-0.86
-60.56%
KALA
KALA BIO
1.03
-296.97
-99.65%
KTTA
Pasithea Therapeutics Corp
0.48
-0.22
-31.71%
SPRC
SciSparc Ltd.
4.90
-61.52
-92.62%
ONCO
Onconetix
0.77
-174.73
-99.56%
60 Degrees Pharmaceuticals, Inc. Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Interim Trial Plan Finalized for Tafenoquine Babesiosis Study
Positive
Jul 9, 2026
On July 7, 2026, 60 Degrees Pharmaceuticals finalized a statistical analysis plan for an interim review of its randomized, placebo-controlled trial of tafenoquine in hospitalized patients with severe babesiosis. The plan sets detailed rules for ti...
Business Operations and Strategy
60 Degrees details tafenoquine priority review voucher strategy
Positive
Jun 3, 2026
60 Degrees Pharmaceuticals disclosed that it plans to apply for a Commissioner’s National Priority Review Voucher if interim or final results from its randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.